Medtronic’s Infuse Bone Graft evaluated in independent review

Medtronic has announced that data from an independent review of its Infuse Bone Graft offering has been published in the Annals of Internal Medicine.

Yale University's third-party assessment of Medtronic's proprietary formulation of recombinant human bone morphogenetic protein-2 (rhBMP-2) provided a clearer picture of the specific benefits and risks associated with this therapy option.

The paper concluded that Infuse offers equivalent clinical success outcomes compared to iliac crest bone graft procedures, while further information was provided on the relationship between rhBMP-2 and cancer incidence rates.

This information will aid physicians by helping to inform their medical decision-making when considering the benefits of anterior lumbar interbody spine fusion.

Dr Rick Kuntz, senior vice-president and chief scientific, clinical and regulatory officer at Medtronic, said: "We will continue to conduct research on rhBMP-2 to further add to an increased understanding of the benefits and risks of this important treatment option."

Last week, the firm announced that its ReDuX Plier, a new instrument specially designed for use during osteotomies, has received European CE Mark approval.